{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:09:46Z","timestamp":1789214986663,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/igc.0b013e3182225509","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T04:13:37Z","timestamp":1312258417000},"page":"1573-1578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Johanna","family":"Hynninen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Auranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsti","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Lavonius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Carpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Perheentupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seija","family":"Gr\u00e9nman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182225509_bb0005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e3182225509_bb0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0090-8258(88)90244-2","article-title":"Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy","volume":"30","author":"Van Der Burg","year":"1988","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdl120","article-title":"CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study","volume":"17","author":"Riedinger","year":"2006","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ygyno.2009.04.019","article-title":"The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer","volume":"114","author":"Rocconi","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2006.02.024","article-title":"Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer","volume":"103","author":"Markman","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0050","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1200\/JCO.2005.06.965","article-title":"Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer","volume":"23","author":"Avril","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e3182225509_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"10.1097\/IGC.0b013e3182225509_bb0060","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24089230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24089230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e3182225509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:08:23Z","timestamp":1753232903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24089230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1048891X24089230"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182225509","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182225509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2011 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}